RSRobin Schaefer

Robin Schaefer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robin Schaefer has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will

    by Mitchell Leus, Chukwunomso E Osakwe, Danjuma Adda, Manal El-Sayed, Jessica Hicks, Yasmin Ibrahim, Philippa C Matthews, Nicaise Ndembi, Theobald Owusu-Ansah, Catherine Wendy Spearman, et al.


  • Open Access

    Multisector global collaboration to advance the inclusion of pregnant and lactating people in HIV prevention research

    by Robin Schaefer, Breanne Lievense, Suzanne Day, Logan Donaldson, Linda-Gail Bekker, Audrey Chigome, Grace Kumwenda, Lisa Noguchi, Chukwunomso Osakwe, Veronica Miller, et al.


  • Open Access

    Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa

    by Robin Schaefer, L. Donaldson, A. Chigome, M. Escudeiro dos Santos, S. Lamprianou, N. Ndembi, J. I. Nwokike, P. Nyambayo, V. Palmi, F. Renaud, et al.

    HIV-prevention efforts focusing on women of child-bearing potential are needed to end the HIV epidemic in the African region. The use of antiretroviral drugs as pre-exposure prophylaxis (PrEP) is a critical HIV prevention tool. However, safety data on new antiretrovirals during pregnancy are often limited because pregnant people are excluded from drug development studies. Calls from communities, healthcare professionals, and regulators to improve the information supporting decision-making around the use of medical products during pregnancy have been increasing. Post-marketing safety surveillance is an essential tool for detecting adverse outcomes and evaluating real-world, longer-term effects of drugs. Detecting and evaluating uncommon pregnancy outcomes requires large sample sizes, highlighting the benefits of and need for safety surveillance. Surveillance systems vary widely across Africa, and the need for enhanced surveillance of PrEP use during pregnancy highlights the limitations of current regulatory and surveillance systems. Challenges include weak regulation and insufficient resources. Pooling of resources and regulatory harmonization could address resource challenges. The African Medicines Agency, as a specialized agency of the African Union, has the potential to improve African medical product regulation, including post-marketing safety surveillance. This can strengthen regulation and ensure that market authorization holders meet their responsibility to invest in post-marketing surveillance systems, such as pregnancy registries. At the same time, independent post-marketing studies are needed to ensure generation of essential safety data. The Forum for Collaborative Research has initiated a project to facilitate interactions between regulators in Africa, the USA, and Europe, as well as other stakeholders, and to work toward consensus on safety data generation from PrEP during pregnancy before and after marketing authorization.


  • Open Access

    Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group

    by Robin Schaefer, Logan Donaldson, Mitchell Leus, Chukwunomso E. Osakwe, Benjamin Chimukangara, Shona Dalal, Ann Duerr, Fei Gao, David V. Glidden, Beatriz Grinsztejn, et al.


  • Open Access

    Twenty‐five years of addressing cutting‐edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research

    by Robin Schaefer, Alessi Ayvaz, Christopher R. Hoffman, Margot Yann, Zachary Rooney, Mitchell Leus, Shilpa Mitra, Veronica Miller, for the Forum for Collaborative Research

    Developing safe and effective drugs and other medical products is a complex and costly process. Drug development has been, historically, commonly competitive and uncollaborative, and this tendency toward a lack of interaction between stakeholders—the pharmaceutical industry, academia, regulatory agencies, healthcare providers, and communities, among others—can lead to missed opportunities to improve efficiency and, ultimately, public health. The Forum for Collaborative Research was established in 1997 to address current scientific, policy, and regulatory issues in global health through multistakeholder engagement and dialogue. By providing a neutral and safe space for discussion, the Forum's model has impacted how clinical trials in diverse health areas are conducted, supported broader and more equitable clinical trial participation, and accelerated delivery of new drugs. The Forum's focus and directions have shifted over time, and this responsiveness to the needs of the global health community will be critical to ensure that the Forum continues to support collaboration in global health. In this article, we present lessons learned from this innovative model of collaborative research and regulatory science, pioneered by the Forum for over 25 years, including the importance of collective ownership and governance by all stakeholders, and emphasis on common goals and advantages of collaboration.


  • Open Access

    Missed opportunities for guidance on sexually transmitted infection services: a global review of national HIV PrEP guidance

    by Erica Spielman, Maeve B Mello, Robin Schaefer, Jason Ong, Heather-Marie A Schmidt, Mary Henderson, Pietro Vinti, Mateo Prochazka, Niklas Luhmann, Rachel Baggaley

    Objectives: People who use or would benefit from pre-exposure prophylaxis (PrEP) for HIV infection are disproportionately affected by sexually transmitted infections (STIs). Integrating STI services when offering PrEP fosters synergies and efficiencies in response to HIV/STI and promotes people-centred care. Including guidance on STI interventions for people on PrEP may facilitate implementation and uptake. We conducted a global review of national PrEP guidance documents and analysed the inclusion of recommendations for the provision of STI services by country level of income.Methods: We searched national PrEP guidance documents published by WHO Member States through the WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS) databases, thePrEPWatchrepository and Google. Information on a range of STI-related interventions was extracted from documents available by October 2023.Results: Of the 113 national PrEP guidance documents retrieved, STIs were mentioned in 77% (90/117). Viral hepatitis B testing and vaccination were recommended by most high-income countries (HICs) and low-income and middle-income countries (LMICs). Recommendation for syphilis testing was prominent in HICs (91%) and moderately noted in LMICs (68%). Gonorrhoea and chlamydia testing was recommended frequently in HICs (88%) and 42% in LMICs. However, the review noted that, to a much lesser extent, specific type of testing for these pathogens was mentioned. Recommendation for quarterly STI testing for syphilis, gonorrhoea and chlamydia was ubiquitous, while the need to offer STI partner services was rarely mentioned.Conclusions: PrEP services offer an opportunity for improved and expanded STI services, increasing person-centred care and addressing STI epidemics alongside HIV. Our review highlights the strengths and gaps in incorporating critical STI interventions into national PrEP normative guidance. Addressing these gaps through a stepwise approach and increasing targeted testing and partner services can help improve quality of care and support an effective response to HIV and other STIs.


  • Open Access

    Long-acting HIV Treatments: Study Design, Logistics, and Access

    by Nicholas A Murdock, Nayri E Alajaji, Robin Schaefer, Cheriko A Boone, Rafael E Campo, Gregory J Dore, Monica Gandhi, J Rafael Gorospe, Roy M Gulick, Sally L Hodder, et al.

    New long-acting HIV treatment products have the potential to change the HIV epidemic in the United States and globally. Phase 3 clinical trials of HIV treatments tend to underrepresent populations bearing a disproportionate burden of the HIV epidemic—including women, racial minorities, trans and gender-diverse people, older adults, the unhoused, people who inject drugs, those in rural areas, individuals with mental illness, and other marginalized groups. These populations commonly face significant challenges in adhering to daily HIV treatment regimens. Conducting clinical trials of long-acting treatment targeting specific unmet medical needs of these populations can improve understanding of optimal care approaches, broaden the indication for use of long-acting products, and inform treatment guidelines, all of which can influence reimbursement and access policies. Innovative trial designs and programmatic implementation can improve inclusivity for long-acting therapy. This article summarizes discussions of a multistakeholder workshop on study designs for long-acting HIV treatments.


  • Open Access

    Young People Need More HIV Prevention Options, Delivered in an Acceptable Way

    by Robin Schaefer, Hortencia Peralta, Mopo Radebe, Rachel Baggaley


  • Open Access

    The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery

    by Mary Henderson, Heather-Marie A Schmidt, Lastone Chitembo, Hortencia Peralta, Ahmed S Alaama, Cheryl Johnson, Rachel Baggaley, Robin Schaefer

    Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.